The Bleeding With Antithrombotic Therapy Study 2
Completed
- Conditions
- Cerebrovascular and Cardiovascular Diseases
- Registration Number
- NCT02889653
- Lead Sponsor
- National Cerebral and Cardiovascular Center, Japan
- Brief Summary
The purpose of this study is to determine the incidence and severity of bleeding complications in patients with cerebrovascular and cardiovascular diseases treated with oral antithrombotic therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5306
Inclusion Criteria
- Patients with cerebrovascular or cardiovascular diseases who start or continue taking oral antithrombotics (antiplatelets and/or anticoagulants) to prevent vascular events
- Patients who are able to receive MRI
- Provision of written informed consent either directly or by a suitable surrogate
Exclusion Criteria
- MRI contraindication
- Any condition that in the opinion of the responsible physician or investigator that renders the patient unsuitable for the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ISTH major bleeding within 2 years
- Secondary Outcome Measures
Name Time Method Ischemic events and those details within 2 years Clinically relevant non-major bleeding within 2 years Hemorrhagic event details within 2 years
Trial Locations
- Locations (9)
St. Marianna University
🇯🇵Kawasaki, Japan
Saga University
🇯🇵Saga, Japan
Tokushima University
🇯🇵Tokushima, Japan
National Cerebral and Cardiovascular Center
🇯🇵Suita, Osaka, Japan
National Hospital Organization Kyushu Medical Center
🇯🇵Fukuoka, Japan
Kobe City Medical Center General Hospital
🇯🇵Kobe, Japan
National Hospital Organization Nagoya Medical Center
🇯🇵Nagoya, Japan
Juntendo University
🇯🇵Tokyo, Japan
Kyorin University
🇯🇵Tokyo, Japan